Abstract:Background:Almost one-third of patients with major depressive disorder (MDD) do not respond to conventional antidepressants, and new treatments for MDD are urgently needed.Objectives:This phase IIb clinical trial was designed to evaluate the efficacy and safety of Anyu Peibo capsules in the treatment of adults with MDD.Design:A multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study.Methods:A total of 172 patients with MDD from nine study centers were randomized (1:1) to receive placebo (n = 86) or oral Anyu Peibo capsules (0.8 g) twice per day (n = 86) for 6 weeks. The primary endpoint was the change in the Montgomery angstrom sberg Depression Rating Scale (MADRS) total score from baseline to week 6, analyzed using an analysis of covariance (ANCOVA) approach with the baseline MADRS score, center effect and center by group interaction as the covariates. Other efficacy endpoints and variables included clinical response and remission rates according to the MADRS and the 17-item Hamilton Depression Rating Scale (HAMD-17) scores, the change in the HAMD-17, Clinical Global Impression - Severity scale and Clinical Global Impression - Improvement scale scores and the reduction in the Hamilton Anxiety Scale from baseline to week 6.Results:The mean baseline MADRS total scores were 29.20 and 29.72 in the Anyu Peibo (n = 82) and placebo groups (n = 81), respectively. The least squares mean change in the MADRS score from baseline to week 6 was 16.59 points in the Anyu Peibo group and 14.51 points in the placebo group. Although there were greater reductions in the MADRS score from baseline to week 6 in the Anyu Peibo capsule group compared to the placebo group, the difference did not reach statistical significance (least-squares mean difference, 2.07 points; 95% confidence interval, -0.27 to 4.41; p = 0.0819). The results of sensitivity analyses by ANCOVA with the last observation carried forward method for missing data indicated that the administration of Anyu Peibo capsules may lead to a significant reduction in depressive symptoms compared to the placebo (least-squares mean difference: 3.29 points; 95% confidence interval: 0.64-5.93; p = 0.0152). Furthermore, Anyu Peibo capsules showed significant benefits over placebo when the change in the HAMD-17 score from baseline to week 6 was evaluated as the secondary analysis (t = 2.01; 95% confidence interval, 0.03-4.23; p = 0.0464).Conclusion:Anyu Peibo capsules may have an effective and safe antidepressant effect, which warrants further research.

Efficacy and Safety of Anjiaxin Capsules in Treatment of Mild or Moderate Depression

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

Efficacy and safety of Jinyukang capsules in the treatment of mild and moderate depression

Randomized,multicenter,double Blind Comparative Trial of Jin-yu-kang Capsule in the Treatment of Mild and Moderate Depression

Randomized, Double Blind, Placebo-Controlled Trial of Shuganjieyu Capsule in the Treatment of Mild or Moderate Depression

Efficacy and safety of double doses of SHUGANJIEYU capsules in treating moderate depressive disor-der:a multicenter, random, double-blind, and parallel-controlled trial

Efficacy and Safety of Morinda Officinalis Oligose Capsule in the Treatment of Mild or Moderate Depression

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Verify the Efficacy and Safety of Ansofaxine (LY03005) for Major Depressive Disorder

Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial

A Randomized Study on Comparing Effect and Safety of Wuling Capsule and Deanxit in Patients with Anxiety or Depression Status

A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults

A Randomized and Double-Blind Clinical Trial of Venlafaxine Hydrochloride Sustained Release Capsules for Treating Juvenile Depression

A Randomized and double-blinded clinical trial of Venlafaxine HCL sustained release capsules for treatment in adolescents with major depression

Randomized, Double Blind, Double - Dummy, Multicenter, Parallel Controlled Clinical Trial of Kaiyuanshen in the Treatment of Depressive Disorder

Multi-center,randomized,and double-blind controlled clinical trial of duloxetine enteric capsule in treatment of depression

Study of Bupropion Hydrochloride Tablet and Fluoxetine in Treatment of Depression Multicenter Clinical Trial

Meta-analysis of Efficacy and Safety of Citalopram and Fluoxetine for Depression in Chinese Patients

Efficacy and Safety of Generic Escitalopram Versus Lexapro in the Treatment of Major Depression: a Multicenter Double-Blinded Randomized Controlled Trial.

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John's Wort for Major Depressive Disorder with Somatic Complaints

A Multicenter Clinical Trial of Wuling Capsule in Treatment of Functional Dyspepsia with Mild to Moderate Depression and Anxiety in Elderly

A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Trial on the Efficacy and Safety of ShuganJieyu Capsule and St. John’s Wort for Major Depressive Disorder with Somatic Complaints